Sanofi, SK Bioscience Launch Phase III Trial Program to Develop PCV21 for Pneumococcal Conjugate Vaccines

admin
Estimated read time 1 min read

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers.

Avatar for admin
admin https://bliolm.com

You May Also Like

More From Author

+ There are no comments

Add yours